LifeMD, Inc. (NASDAQ:LFMDP) Short Interest Up 525.0% in March

LifeMD, Inc. (NASDAQ:LFMDP) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,500 shares, a growth of 525.0% from the March 15th total of 400 shares. Based on an average trading volume of 3,600 shares, the short-interest ratio is presently 0.7 days.

LifeMD Stock Performance

LFMDP traded up $0.26 during trading on Monday, hitting $23.40. The stock had a trading volume of 58,705 shares, compared to its average volume of 3,479. The company has a 50 day moving average price of $23.30 and a 200-day moving average price of $22.68. LifeMD has a one year low of $20.25 and a one year high of $27.44.

LifeMD Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, April 4th will be given a $0.5547 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.22 dividend on an annualized basis and a dividend yield of 9.48%.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.